Even though the immunotherapy approaches or IFN-γ treatment in myeloproliferative diseases yet to be developed, our findings indicate the unfavorable actions of IFN-γ which may be targeted to support the anti-tumor responses and increase the efficacy of immune intervention therapies in myeloproliferative diseases. Here, IFNG is linked to neoplasm.